SPDR® S&P Pharmaceuticals ETF

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///Chart  USST
    Earnings Report

    Behind Allergan’s US Specialized Therapeutics Segment in 1Q17

    In 1Q17, Allergan’s US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.

    By Mike Benson
  • uploads///Chart  Cardiovascular
    Earnings Report

    How Eli Lilly’s Cardiovascular Franchise Performed in 1Q16

    Eli Lilly’s (LLY) cardiovascular franchise contributed ~15.5% of the company’s total revenues in 1Q16.

    By Mike Benson
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    Merck’s Gardasil and Other Human Vaccines in 3Q17

    Merck & Co.’s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Allergan’s Business Segments in 1Q18

    Allergan’s US Specialized Therapeutics business revenues rose 6.5% to $1.6 billion during 1Q18, compared to $1.5 billion during 1Q17.

    By Mike Benson
  • uploads///ibrance
    Company & Industry Overviews

    Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

    Since its launch in February 2015, Pfizer’s Ibrance has quickly captured the advanced breast cancer market and has reached more than 40,000 patients.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///Acq
    Company & Industry Overviews

    Mylan’s Recent Acquisitions Continue to Strengthen Its Position in International Markets

    Mylan takes an M&A strategy to save time related to compliance activities for obtaining regulatory approvals across various international markets.

    By Seth Richards
  • uploads///Chart
    Company & Industry Overviews

    A Look at Pfizer’s Revenue Trends

    Pfizer (PFE) reports revenue in two business segments: Innovative Health and Essential Health.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Allergan on April 27

    Allergan’s earnings per share are estimated to be $3.36 for 1Q18, compared to earnings per share of $3.35 for 1Q17.

    By Mike Benson
  • uploads///Chart  ASCO
    Company & Industry Overviews

    Pfizer’s Highlights from the 54th Annual Meeting of ASCO

    The 54th Annual Meeting of the American Society of Clinical Oncology (or ASCO) was held in Chicago from June 1 to June 5.

    By Mike Benson
  • uploads/// Trump
    Company & Industry Overviews

    Analyzing Donald Trump’s Free-Market Healthcare

    While Clinton aims to retain and bolster the Affordable Care Act, Trump wants to replace it with a new act that encourages free-market competition.

    By VanEck
  • uploads///Chart  LLY
    Company & Industry Overviews

    Eli Lilly Stock’s June Performance

    Leading US pharmaceutical company Eli Lilly (LLY) specializes in human pharmaceuticals and animal health.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb’s Profit Margins in 4Q17

    Bristol-Myers Squibb’s (BMY) revenue grew 4% to $5.5 billion in 4Q17, driven by 2% operational revenue growth and a 2% boost from foreign currency translation.

    By Mike Benson
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • uploads///JNJ
    Healthcare

    JNJ Stock Emerging from a Dark Decade

    In 2019, JNJ stock’s 12% return has lagged the S&P’s 27% return by a wide margin. JNJ has lagged the SPDR S&P Pharmaceuticals ETF (XPH) by 2%.

    By Michael Bracken
  • uploads///BMYcelgene
    Company & Industry Overviews

    What to Expect from BMY’s Celgene Acquisition

    The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

    By Daniel Collins
  • uploads///Chart
    Healthcare

    Comparing Pfizer Stock and Eli Lilly Stock

    Eli Lilly and Company (LLY) stock has fallen a marginal ~0.1% so far in September, and its closing price was $105.59 on September 24.

    By Mike Benson
  • uploads///Chart
    Healthcare

    A Closer Look at the Allergan–Bonti Deal

    On September 14, Allergan (AGN) announced the acquisition of Bonti Inc., a clinical-stage biotechnology company.

    By Mike Benson
  • uploads///Chart  ETFs
    Healthcare

    How Pharmaceutical ETFs Have Performed in 2018

    The SPDR S&P Pharmaceuticals ETF holds ~5.0% of its total investments in Eli Lilly and Company (LLY).

    By Mike Benson
  • uploads///medic _
    Company & Industry Overviews

    Pfizer Announces Results for JAVELIN Renal 101 Study

    Pfizer (PFE) and Merck announced in a press release today positive top-line results for their JAVELIN Renal 101 study, which evaluated a combination of Bavencio (avelumab) and Inlyta (axitinib).

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s Q2 2018 Earnings: Elanco

    Elanco reported revenues of $792.1 million in Q2 2018, representing 1.0% YoY growth from $784.8 million in Q2 2017.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Pfizer’s Xeljanz Receives Marketing Authorization in EU

    On August 1, Pfizer announced that the European Commission approved Xeljanz for the treatment of ulcerative colitis.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    Allergan Reports Strong Revenue Growth and Q2 2018 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting non-GAAP EPS of $4.42 on revenues of $4.1 billion.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Pfizer’s EC Approval of Xeljanz for Active Psoriatic Arthritis

    Pfizer (PFE) announced in a press release yesterday that the European Commission has approved its marketing authorization application for Xeljanz in combination with methotrexate for active psoriatic arthritis.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s US Specialized Therapeutics Segment

    Allergan’s (AGN) US Specialized Therapeutics segment includes revenue from the US sales of specialized products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Endocrine Products Performed in 4Q17

    Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment includes the endocrine products Humalog, Humulin, and Forteo.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Business Segments Performed

    Merck reported 3% growth in revenues to ~$10.4 billion during 4Q17 as compared to 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Pfizer Products Saw Declining Sales in 4Q17

    A few products in Pfizer’s (PFE) portfolio reported declining sales in 4Q17 following their loss of market share to the competition.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Comparing Eli Lilly’s Post-4Q17 Valuation

    Eli Lilly’s valuation In 4Q17, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ EPS (earnings per share) and revenue estimates of $1.07 and ~$5.9 billion, respectively, reporting EPS of $1.14 on revenue of ~$6.2 billion. The above chart shows Eli Lilly’s EPS and revenue since 1Q16. In fiscal 2017, Eli Lilly reported EPS of $4.28 on […]

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Pfizer’s Valuation after 4Q17 Earnings?

    Pfizer (PFE) reported 1% growth in revenues to $13.7 billion during 4Q17 as compared to revenues of $13.6 billion during 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Eli Lilly’s 4Q17 Estimates: Elanco

    Elanco is expected to report growth in revenues during 4Q17, following strong sales and a favorable impact of foreign exchange.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Business in 4Q17

    Johnson & Johnson (JNJ) reported ~48.0% of its total revenues from the Pharmaceuticals business during 4Q17, making it the company’s largest revenue contributor.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer: Revenue Growth Is Expected in 4Q17

    Wall Street analysts expect Pfizer’s (PFE) revenues to increase ~0.7% to $13.72 billion during 4Q17—compared to revenues of $13.63 billion during 4Q16.

    By Mike Benson
  • uploads///Chart  AH
    Company & Industry Overviews

    Merck & Co.’s Animal Health Business in 3Q17

    Merck’s (MRK) Animal Health segment’s total revenues increased ~16% to $1 billion in 3Q17 compared to $865 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Revenue Estimates for 4Q17

    Johnson & Johnson’s (JNJ) Pharmaceutical segment contributes more than 45% to total revenues. In 4Q17, it’s expected to report growth in operating revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Developments for Mylan

    Recent developments reported by Mylan (MYL) include commercial developments as well as product developments. Let’s take a closer look.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Valuation in December 2017

    On December 27, 2017, Johnson & Johnson (JNJ) was trading at a forward price-to-earnings multiple of ~17.8x compared to the industry average of 15.8x.

    By Mike Benson
  • uploads///Chart  BS
    Company & Industry Overviews

    Eli Lilly’s Business Segments in 3Q17

    Eli Lilly’s human pharmaceuticals segment contributed ~87% of Eli Lilly’s total revenues in 3Q17.

    By Mike Benson
  • uploads///NET SALES EPS GROWTH MYL
    Consumer

    Mylan: How Its Performance Contributed to Its Valuation

    In this final series of our three-part series, we’ll be looking at the last seven stocks among the top 18 cheap stocks in the S&P 500 for 2018.

    By Amanda Lawrence
  • uploads///Celebrex
    Company & Industry Overviews

    A Look at How These Pfizer Drugs Have Performed in 2017

    In 3Q17, Pfizer’s (PFE) Celebrex generated revenues of $212 million, a ~9% increase on a year-over-year (or YoY) basis and a 19% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  New
    Company & Industry Overviews

    Eli Lilly’s New Pharmaceutical Products in 3Q17

    Eli Lilly’s (LLY) new products include Basaglar, Cyramza, Jardiance, Lartruvo, Olumiant, Taltz, and Trulicity.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Merck’s 3Q17 Revenues Could Rise

    Analysts expect Merck’s (MRK) revenues for 3Q17 to be around $10,546 million, nearly a 0.1% increase as compared to the revenues of $10,536 million reported for 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Factors Affected Johnson & Johnson’s Revenues in 2Q17

    Johnson & Johnson (JNJ) reported a 2.9% increase in its revenues at constant exchange rates in 2Q17.

    By Mike Benson
  • uploads///Chart  Revenues
    Company & Industry Overviews

    Pfizer’s Revenues in Review: PFE’s Quarterly Performance

    Pfizer (PFE) reported revenues of ~$12.9 billion in 2Q17, which was ~2% lower than its revenues of ~$13.2 billion in 2Q16.

    By Mike Benson
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    Introducing Merck’s 2Q17 Immuno-Oncology Blockbuster

    For 2Q17, Keytruda reported revenues of $881 million, which represents 183% growth at constant exchange rates.

    By Mike Benson
  • uploads///Chart  Cardio
    Company & Industry Overviews

    Eli Lilly’s Cardiovascular Products in 2Q17

    Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company’s total revenues.

    By Mike Benson
  • uploads///Chart  Eliquis
    Company & Industry Overviews

    Performance of Bristol-Myers Squibb’s Eliquis in 2Q17

    Bristol Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Defitelio Continues to Demonstrate Robust Demand Trends in 2017

    Jazz Pharmaceuticals expects Defitelio to report revenues in the range of $130 million to $150 million globally in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Jazz Is Expected to Report a Robust Revenue Growth Rate

    On August 3, JAZZ managed to secure regulatory approval from the FDA for its innovative drug, Vyxeos, as a treatment option for two types of acute myeloid leukemia.

    By Margaret Patrick
  • uploads///Chart  Virology
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Virology Products

    Bristol-Myers Squibb’s (BMY) virology portfolio includes drugs for the treatment of chronic viral diseases and infections such as hepatitis B, hepatitis C, and HIV.

    By Mike Benson
  • uploads///Chart  Rev
    Company & Industry Overviews

    Understanding Allergan’s Revenue Stream for 2017

    Allergan’s revenues are driven by the strong performance of products under its key brands as well as the inclusion of revenues from LifeCell and other acquisitions.

    By Mike Benson
  • uploads///Chart  ETFs
    Miscellaneous

    A Look at Pharmaceutical ETFs in 2Q17

    Pharmaceutical ETFs Pharmaceutical ETFs are securities designed for investors who do not have the capacity to hold many stocks but are interested in diversification of their investments within the pharmaceutical sector. Besides diversification, ETFs have other benefits, such as the ability to sell short, buy on margin, and purchase a single unit. Also, the expense […]

    By Mike Benson
  • uploads///Chart  LMS
    Company & Industry Overviews

    Why Pfizer’s Products Lost Market Share in 1Q17

    There are a few products in Pfizer’s (PFE) portfolio that are losing market share due to competition.

    By Mike Benson
  • uploads///Chart  Cardio
    Earnings Report

    Eli Lilly’s 1Q17 Earnings: Cialis and Other Cardiovascular Products

    Cialis sales decreased over 7% to $533.6 million during 1Q17, compared to $576.7 million for 1Q16.

    By Mike Benson
  • uploads///Chart  Consumers
    Earnings Report

    Johnson & Johnson’s Consumer Segment’s 1Q17 Earnings

    Johnson & Johnson’s Consumer segment’s revenue rose 1.0% year-over-year to $3.2 billion in 1Q17. This rise included an operational rise of 0.8% and the positive impact of foreign exchange.

    By Mike Benson
  • uploads///National Health Expenditure as of
    Macroeconomic Analysis

    The Hybrid US Healthcare System: An Overview

    The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare.

    By Mary Sadler
  • uploads///Chart
    Company & Industry Overviews

    Gardasil Driving Merck & Co.’s Vaccines Business in 4Q16

    The total sales for MRK’s Gardasil franchise during 4Q16 totaled $542 million, an increase of ~9% over $497 million for 4Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales

    Mylan’s fall in revenues was driven by lower sales and lower wholesale purchases of the EpiPen Auto-Injector in anticipation of the generic version.

    By Mike Benson
  • uploads///pfizers patents
    Company & Industry Overviews

    Loss of Patent Protection to Drag Pfizer’s Top Line

    With the loss of patent protection for its flagship drug, Lipitor, Pfizer’s revenue fell to $48.8 billion in 2015, compared to $67 billion in 2010.

    By Jillian Dabney
  • uploads///Acthar
    Company & Industry Overviews

    Where Else Have We Seen Mallinckrodt’s ‘Acquire to Invest’ Strategy?

    The business strategies of both Mallinckrodt and Valeant reflect what the former refers to as “Acquire to Invest.”

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Januvia and Janumet: Merck’s Blockbuster Diabetes Products

    Januvia and Janumet together contributed about 14.7% of Merck’s (MRK) total revenues for 3Q16, an ~0.9% decrease compared to 3Q15.

    By Mike Benson
  • uploads///Opdivo and keytruda
    Company & Industry Overviews

    Keytruda Leads over Opdivo in Head and Neck Cancer Treatment

    CheckMate-141 Bristol-Myers Squibb’s (BMY) CheckMate-141 evaluated Opdivo for the treatment of squamous cell carcinoma of the head and neck. The study was stopped after meeting the primary endpoint in January 2016. The drug is under priority review by the FDA with an action date set for November 11, 2016. With similar approved indications, Opdivo and Merck’s (MRK) […]

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    A Look at Gardasil and Merck & Co.’s Vaccines Business

    Gardasil, a vaccine for the prevention of strains of the human papillomavirus (or HPV) that are sexually transmitted, is Merck & Co.’s leading vaccines franchise.

    By Mike Benson
  • uploads///deal benefits
    Company & Industry Overviews

    News of Acquisition Caused Horizon Pharma Stock to Rise

    The market was pleased with the merger deal between Horizon Pharma (HZNP) and Raptor Pharmaceuticals. HZNP shares rose to $18.89 on September 12.

    By Jillian Dabney
  • uploads///Chart  Animal
    Company & Industry Overviews

    Animal Health: Just as Important to Eli Lilly as Human Health

    Eli Lilly and Co.’s (LLY) animal health company, Elanco, reported an increase of 2% in revenues at $860 million in 2Q16—compared to $841 million in 2Q15.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Akorn in 2016: What Are Its Key Risk Factors?

    In addition to industry-specific risks faced by all generic pharmaceutical players, Akorn (AKRX) faces certain company-specific risks.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Are Merck’s Key Diabetes Products?

    Januvia and Janumet are two blockbuster drugs in Merck’s (MRK) diabetes franchise.

    By Mike Benson
  • uploads/// Sales estimates
    Company & Industry Overviews

    What’s Really Driving Horizon’s Valuation?

    In 1Q16, Horizon Pharm’s sales on a YoY basis grew by 81% to $205 million. During that period, its adjusted EBITDA jumped annually by 122% to $72 million.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Januvia and Janumet: Merck’s Blockbuster Diabetes Drugs

    Januvia and Janumet are Merck & Co.’s (MRK) blockbuster diabetes drugs. They’re are used to lower blood sugar levels in patients with Type 2 diabetes.

    By Mike Benson
  • uploads///acquisitions
    Company & Industry Overviews

    How Horizon Became a Growth Stock

    Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.

    By Jillian Dabney
  • uploads///TEVA OTC Others Part
    Earnings Report

    Insight into Teva’s Over-the-Counter and Distribution Businesses

    According to Teva, the biggest challenge for its OTC segment is foreign exchange fluctuations. It generates all of its revenue in non-US dollars and then reports back in US dollars.

    By Peter Neil
  • uploads///Therapeutic Area
    Company & Industry Overviews

    Mylan Product Portfolio across Key Therapeutic Areas

    Mylan is a leading pharmaceutical company that operates in more than 140 countries and operates across five different therapeutic areas.

    By Seth Richards
  • uploads///Prescription Drug
    Company & Industry Overviews

    Sizing up Mylan’s Blockbuster Drugs: Perforomist, Ultiva, and Emsam

    Mylan NV is the generic drug leader in the US prescription drug market with blockbuster drugs such as Perforomist, Ultiva, and Emsam.

    By Seth Richards
  • uploads///Article
    Company & Industry Overviews

    How to arrive at valuations for big pharma

    The PE ratio for global big pharma increased from 14.9x in 2011 to 26x in 2014. This trend is a measure of increasing investor confidence.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.